Crossmark

FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN)

Crossref DOI link: https://doi.org/10.1007/s00277-024-05867-w

Published Online: 2024-07-05

Published Print: 2024-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Isfort, Susanne

von Bubnoff, Nikolas

Al-Ali, Haifa Kathrin

Becker, Heiko

Götze, Thorsten

le Coutre, Philipp

Griesshammer, Martin

Moskwa, Claudia

Wohn, Luisa

Riedel, Johanna

Palandri, Francesca

Manz, Kirsi

Hochhaus, Andreas

Döhner, Konstanze

Heidel, Florian H.
Funding

Funding for this research was provided by:

Medizinische Hochschule Hannover (MHH)
License Information

Text and Data Mining valid from 2024-07-05

Version of Record valid from 2024-07-05
More Information

Article History

Received: 24 May 2024

Accepted: 25 June 2024

First Online: 5 July 2024

Declarations

:

: Not applicable.

: TG, LW and JR are employed by the IKF Frankfurt GmbH, which acts as the sponsor of this trial.

Document is current

Any future updates will be listed below